Blockade of IL-23R in human IBD animal models can often decrease gut inflammation (Buonocore et al., 2010; Parigi et al., 2022), while protective IL-22 production from ILC3s requires the stimulation of IL-23R on ILC3 (Geremia et al., 2011). Here, IL22 is linked to inflammatory bowel disease.